In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...

In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...

Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The ...

Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Merck (NYSE: MRK), known ...

AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and ...

New findings reveal pulmonary arterial hypertension may affect the brain early. Learn how inflammation and cognitive decline ...

PAH is a disorder of vasoconstriction and proliferation, and treatment focuses on medications that act on or reverse these specific events. Conventional therapy consists of diuretics, oxygen, ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries in your lungs. It happens when these arteries become narrow or blocked, making it harder for blood to flow ...

The algorithm integrates with EHR systems and ECG platforms, operating within the health system without external data ...

Pulmonary hypertension is characterized by increased BP in the pulmonary vasculature You will want your patients to consult a specialist to slow progression of this debilitating disease. Here's what ...